# Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

> **NCT07480356** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Protara Therapeutics** · enrollment: 284 (estimated)

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

## Interventions

- **DRUG:** TARA-002
- **DRUG:** Investigator's Choice of Intravesical Chemotherapy

## Key facts

- **NCT ID:** NCT07480356
- **Lead sponsor:** Protara Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-04
- **Final completion:** 2032-11
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07480356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07480356, "Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07480356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*